Impax Pharmaceuticals Announces Amendment of Co-Promotion Agreement Pfizer Inc.

HAYWARD, Calif.--(BUSINESS WIRE)--Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (NASDAQ: IPXL), today announced that it has amended its 2008 co-promotion agreement with Wyeth, now a wholly owned subsidiary of Pfizer. Impax will now detail Lyrica® (pregabalin) CV for use as adjunctive therapy for adult patients with partial onset seizures to neurologists effective April 1st. Impax will discontinue detailing Pristiq® (desvenlafaxine extended-release tablets).